Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates

Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead and a strengthened balance sheet. ASMB's pipeline targets high-unmet-need indications—recurrent genital herpes, HDV, and cholestatic liver diseases—with differentiated mechanisms and strong early clinical data. Pro forma liquidity exceeds $340 million post-offering, supporting operations through 2028 and enabling strategic optionality without near-term capital needs. ASMB trades at a notable valuation discount to peers, despite Gilead collaboration, multiple clinical-stage assets, and upcoming Phase 2/3 catalysts.

I believe Assembly Biosciences (ASMB) has transitioned from being a small-cap pre-commercial biotech developing its early antiviral products in a high-risk development environment into an antiviral development platform. With a large strategic partner underpinning